STAT+: GSK sees its return to cancer starting to pay off
A decade ago, GSK was out of oncology. It could soon pick up approval for its sixth cancer drug.
2 across the spectrum. Choose a side on the bar to jump to it.
National story. 2 articles from 2 sources. Updated 7d ago.